Table 1.
Baseline disease characteristics.
| Crohn’s disease [n = 37] |
Ulcerative colitis [n = 21] |
|
|---|---|---|
| Sex, women, n [%] | 15 [40.5] | 9 |
| Disease duration, y, median [IQR] | 4.6 [2.6–16.3] | 5.0 [1.8–9.6] |
| Age at inclusion, y, median [IQR] | 30.2 [22.9–41.6] | 37.5 [26.2–47.2] |
| Disease location, n [%] | L1 Ileal disease—10 [27] | E1 Proctitis—3 [14.3] |
| L2 Colonic disease—9 [24.3] | E2 Left sided—8 [38.1] | |
| L3 Ileocolonic disease—18 [48.6] | E3 Pancolitis—10 [47.6] | |
| Disease behavior, n [%] | ||
| Inflammatory [B1] | 22 [59.5] | |
| Stricturing [B2] | 5 [13.5] | NA |
| Penetrating [B3] | 10 [27.0] | |
| Perianal disease [p] | 12 [32.4] | |
| Smoking status, n [%] | ||
| Active smoking | 7 [18.9] | 0 [0.0] |
| Previously smoking | 10 [27.0] | 6 [28.6] |
| Never smoked | 20 [54.1] | 15 [71.4] |
| Body Mass Index, kg/m2, median [IQR] | 21.6 [19.8–25.3] | 22.9 [22.0–26.4] |
| C-reactive protein, mg/L, median [IQR] | 12.5 [3.5–22.1] | 5.9 [1.5–20.7] |
| Fecal calprotectin, μg/g, median [IQR] | 1800.0 [1554.2–1800.0] | 1800.0 [924.8–1800.0] |
| PRO2, median [IQR] | 15.0 [7.0–21.0] | 4.0 [4.0–5.0] |
| Initiated biological therapy, n [%] | ||
| Adalimumab | 5 [13.5] | 4 [19.0] |
| Infliximab | 8 [21.6] | 5 [23.8] |
| Vedolizumab | 12 [32.4] | 12 [57.1] |
| Ustekinumab | 12 [32.4] | NA |
| Timing of endoscopic assessment, weeks, median [IQR] | 23.7 [22.4–24.7] | 13.7 [11.0–14.3] |
IQR = interquartile range; n = number of patients; PRO2 CD = patient-reported outcome for Crohn’s disease = 5 × abdominal pain score + 2 × liquid stool frequency; PRO2 UC = patient-reported outcome for ulcerative colitis = stool frequency + rectal bleeding.